CELL MEDX CORP. (OTCMKTS:CMXC) Files An 8-K Regulation FD Disclosure
ITEM 7.01
|
REGULATION FD DISCLOSURE
|
informational news release (the Release) announcing the
engagement of Think Ink Marketing Data Email Services, Inc.
(Think Ink) to develop an investor outreach program for the
Company. A copy of the Release is attached to this Current Report
on Form 8-K as Exhibit 99.1.
Form 8-K and Exhibit 99.1 shall not be deemed to be filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, unless the Company specifically
states that the information is to be considered filed under the
Exchange Act or incorporates it by reference into a filing under
the Securities Act of 1933, as amended, or the Exchange Act.
Report or are incorporated herein by reference:
|
Exhibit Number
|
Description of Exhibit
|
|
99.1
|
News Release dated February 24, 2017.
|
About CELL MEDX CORP. (OTCMKTS:CMXC)
Cell MedX Corp. is a development-stage company focused on the discovery, development and commercialization of therapeutic products for patients with diseases, such as diabetes, by developing technologies to help manage the illness and related complications. The Company, through its subsidiary, Avyonce Cosmedics Inc. (Avyonce), is engaged in reselling and marketing spa technology and equipment to the beauty and wellness industry. Avyonce is involved in carrying out observational studies using eBalance Technology. The eBalance Technology is used for the use of micro currents for the treatment of diabetes and related ailments. Avyonce also provides continuing education to the estheticians and healthcare professionals in the field of medical aesthetics. The Company is engaged in developing a family of devices based on the eBalance Technology. CELL MEDX CORP. (OTCMKTS:CMXC) Recent Trading Information
CELL MEDX CORP. (OTCMKTS:CMXC) closed its last trading session up +0.030 at 0.280 with 1,588 shares trading hands.